News and Trends 17 Aug 2022 Sanofi drops amcenestrant clinical development program Sanofi says it is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision was based on the outcome of an interim analysis of the phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive […] August 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Merck puts up to $37B into Orna Therapeutics circular RNA collaboration Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech company working on a new investigational class of engineered circular RNA (oRNA) therapies, are to collaborate on discovering, developing, and commercializing multiple programs, including vaccines and therapeutics, in the areas of infectious diseases and oncology. Under the terms of the […] August 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies The first patient has been dosed in a phase 1 trial evaluating a monotherapy treatment in people with advanced solid tumors and hematologic malignancies in Australia. Antengene Corporation Ltd., is running the ATRIUM trial, a phase 1 multi-center, open-label, dose-finding study of monotherapy ATG-018. Safety and tolerability of ATG-018 The primary objective of the study […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock ADC Therapeutics has announced a series of major strategic transactions involving hundreds of millions of dollars allowing it to advance its lead candidate and pipeline drugs. The Swiss company has entered into a new $175 million senior secured loan with certain funds of Owl Rock – a division of Blue Owl Capital, Inc. and funds […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Inhibrx chondrosarcoma treatment gets EC orphan medicinal product designation Following a positive opinion from the European Medicines Agency (EMA), the European Commission (EC) has granted orphan medicinal product designation to Inhibrx, Inc. for INBRX-109 for the treatment of chondrosarcoma. “We are highly optimistic about the potential of INBRX-109 in chondrosarcoma to address a high unmet medical need,” said Inhibrx CEO, Mark Lappe. “The positive […] August 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Genentech lymphoma treatment gets FDA approval Genentech, a part of the Roche Group, says the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy. Polivy (polatuzumab vedotin-piiq), in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). The FDA […] August 16, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors Regen BioPharma, Inc. has filed with the United States Patent and Trademark Office a provisional U.S. patent application covering the company’s novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion.” CAR-T cells are effective at treating certain lymphomas and leukemias with […] August 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 First patient enrolled on Panbela’s trial for treatment of pancreatic cancer Panbela Therapeutics, a U.S.-based clinical stage company, announced today (August 11) that it has enrolled its first patient in a global trial to evaluate a potential cure for pancreatic cancer. The trial referred to as ASPIRE will involve studying SBP-101, a treatment for metastatic pancreatic ductal adenocarcinoma. It is a randomized, double-blind placebo-controlled, trial with […] August 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 Acquisition of TeneoTwo and its clinical-stage T-cell engager completed AstraZeneca has said today (August 11) that it has completed its purchase of TeneoTwo including its B-cell non-Hodgkin lymphoma drug candidate. The company made an upfront payment of $100 million and then additional payments of up to $805 million contingent on research and development milestones as well as up to $360 million to TeneoTwo’s former […] August 11, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Research discovery may help diagnose and treat cancer and brain disorders Researchers at Queen’s University Belfast in Northern Ireland have revealed how the pathway of an identified protein could lead to early diagnosis and targeted treatment for several cancers and brain disorders. The team of researchers discovered how the journey or molecular pathway of an identified protein is both essential for brain development and how an […] August 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma A Polish biopharma company focused on treating cancer and autoimmune diseases announced today (August 10) that it has chosen a lead candidate for the treatment of hepatocellular carcinoma. The molecular glue candidate, CPT-6281 will be Captor Therapeutic’s CT-01 project which will initially focus on the clinical development of the asset as a targeted protein degradation […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment A global collaboration was announced today (August 9) between Mersana Therapeutics Inc and GSK plc that will give GSK the option to co-develop and commercialize an antibody drug conjugate (ADC). The ADC called XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells. Anna […] August 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email